Curtis Thorne, PhD, and UA doctoral student Carly Cabel validated findings from a 2018 collaborative study that identified a possible new therapeutic target for colon cancer – after a Harvard lab challenged the initial results.Continue reading→

Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares.

Castle Biosciences is a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.

The company is headquartered in Friendswood, Texas and has Laboratory/Clinical Operations in Phoenix, Arizona.  

Continue reading→

Arizona State University announced today that it has been selected by the U.S. Defense Advanced Research Projects Agency (DARPA) to build a field-deployable, point-of-care device that will determine in 30 minutes or less if a person has been exposed to weapons of mass destruction or their precursors. The DARPA award, worth up to $38.8 million over four years in phases and options, will build on the university’s growing capabilities in developing molecular diagnostics for applications in defense and human health.Continue reading→

TGen and Tufts University novel findings for this deadly bone cancer could lead to better treatments for people and pets
Continue reading→

With more people turning to their smartphones to complement their medical care, and the number of apps flooding the marketplace, how can a new consumer health app catch the attention of investors?Continue reading→

First Biosimilar Avastin® and Herceptin® Products to Launch in the United StatesContinue reading→

Continue reading→

The Arizona Behavioral  Health Corporation is accepting applications for  the 2019  Eric Gilbertson Advocacy Institute for Behavioral Health.  The program includes six days of advocacy training and a comprehensive overview of Arizona’s behavioral health systemContinue reading→